#United States #New York #Pomerantz LLP #Fulgent Genetics #FLGT

Pomerantz Law Firm Investigates Claims Against Fulgent Genetics, Inc.

Pomerantz LLP, a reputed law firm specializing in corporate and securities class action litigation, has launched an investigation into potential claims on behalf of investors of Fulgent Genetics, Inc. (NASDAQ: FLGT). This inquiry is significant as it may unravel allegations of securities fraud or other illegal practices involving the biotechnology company. Investors are encouraged to reach out to Pomerantz to discuss their rights and potential involvement in any legal proceedings related to these claims.

Context of the Investigation

On February 28, 2025, Fulgent Genetics disclosed that it had received a civil investigative demand from the U.S. Department of Justice. This demand concerns allegations of false claims that may have been submitted under the Uninsured Program. Such revelations have led to considerable concern among investors, particularly regarding the company’s compliance with federal regulations and ethical business practices.

Following this announcement, Fulgent’s stock price saw a noticeable dip, declining by $0.41 per share or 2.61% over just two trading sessions. By March 3, 2025, the stock closed at $15.28 per share. The immediate market reaction underscores the gravity of the situation and the potential ramifications for those involved with Fulgent Genetics.

About Pomerantz LLP

Established over 85 years ago by Abraham L. Pomerantz, widely recognized as the dean of the class action bar, Pomerantz LLP has built a reputation for fighting for investors’ rights in cases of securities fraud, breaches of fiduciary duty, and corporate misconduct. The firm boasts a resilient track record, including significant multimillion-dollar settlements on behalf of class members who have suffered losses due to unethical practices by corporations.

Pomerantz’s dedication is informed by a commitment to uphold the principles of justice and accountability in corporate America. With offices in major cities like New York, Chicago, and Los Angeles, Pomerantz is strategically positioned to assist investors across the nation.

Taking Action

Investors who wish to engage with Pomerantz regarding their possible claims against Fulgent Genetics are encouraged to reach out to Danielle Peyton at the firm. This engagement could provide them with essential insights into their rights and the steps they might take as legal proceedings unfold. Potential claimants can contact Ms. Peyton via email or phone for more information about the investigation and how to participate in any upcoming class action litigation.

In this rapidly changing landscape, understanding the implications of these legal challenges is vital for investors hoping to safeguard their interests and recover any potential losses associated with their investments in Fulgent Genetics.

In summary, Pomerantz LLP’s investigation into Fulgent Genetics may uncover critical truths regarding the company's business practices and their compliance with federal laws. As this situation develops, it is imperative for affected investors to stay informed and proactive in defending their rights.

For further information, interested parties should visit Pomerantz’s official website or reach out directly using the contact information provided above.